| David M Hogle, MD | |
|
1995 Errecart Blvd Ste 103, Elko, NV 89801-8336 | |
| (775) 738-3111 | |
| (775) 778-6728 |
| Full Name | David M Hogle |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 48 Years |
| Location | 1995 Errecart Blvd Ste 103, Elko, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245395623 | NPI | - | NPPES |
| 3967 | Other | NV | STATE LICENSE |
| 002004353 | Medicaid | NV | |
| CS03084 | Other | NV | STATE PHARMACY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 3967 (Nevada) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New Horizon Home Care, Llc | Elko, NV | Home health agency |
| Genesis Home Health Services | Elko, NV | Home health agency |
| Northeastern Nevada Regional Hospital | Elko, NV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hogle Miller And Ward Professional Corporation | 8022908375 | 2 |
News Archive
The latest advances in both breast cancer treatment and research - including innovations in diagnostic, surgical, chemotherapy and radiation approaches - will be discussed Friday, April 8, 2011, at a breast cancer symposium at the Kimmel Cancer Center at Jefferson in Philadelphia.
On September 24th at 7:00pm EDT, Dr. Holly Andersen, Director of Education and Outreach at the Ronald O. Perelman Heart Institute at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, will host a live webcast exploring the advances and innovations in the treatment of cardiovascular disease. The air live on ORLive.com from the Hospital's new Ronald O. Perelman Heart Institute.
Itamar-Medical, the world's leader of non-invasive devices for diagnosis of cardiovascular health, announced achievement of the next milestone of the international pharmaceutical company, Roche, to further develop the EndoPAT technology for pre-clinical trials.
Watson Pharmaceuticals, Inc. has announced that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for albuterol sulfate inhalation solution in the 0.021% (base) and 0.042% (base) strengths.
An international research team, led by the University of Bristol, has provided the first clues to understand how the mcr-1 gene protects bacteria from colistin - a 'last resort' antibiotic used to treat life-threatening bacterial infections that do not respond to other treatment options.
› Verified 4 days ago
| Entity Name | Hogle Miller & Ward Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720144579 PECOS PAC ID: 8022908375 Enrollment ID: O20040318001523 |
News Archive
The latest advances in both breast cancer treatment and research - including innovations in diagnostic, surgical, chemotherapy and radiation approaches - will be discussed Friday, April 8, 2011, at a breast cancer symposium at the Kimmel Cancer Center at Jefferson in Philadelphia.
On September 24th at 7:00pm EDT, Dr. Holly Andersen, Director of Education and Outreach at the Ronald O. Perelman Heart Institute at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, will host a live webcast exploring the advances and innovations in the treatment of cardiovascular disease. The air live on ORLive.com from the Hospital's new Ronald O. Perelman Heart Institute.
Itamar-Medical, the world's leader of non-invasive devices for diagnosis of cardiovascular health, announced achievement of the next milestone of the international pharmaceutical company, Roche, to further develop the EndoPAT technology for pre-clinical trials.
Watson Pharmaceuticals, Inc. has announced that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for albuterol sulfate inhalation solution in the 0.021% (base) and 0.042% (base) strengths.
An international research team, led by the University of Bristol, has provided the first clues to understand how the mcr-1 gene protects bacteria from colistin - a 'last resort' antibiotic used to treat life-threatening bacterial infections that do not respond to other treatment options.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David M Hogle, MD 1995 Errecart Blvd Ste 103, Elko, NV 89801-8336 Ph: (775) 777-0216 | David M Hogle, MD 1995 Errecart Blvd Ste 103, Elko, NV 89801-8336 Ph: (775) 738-3111 |
News Archive
The latest advances in both breast cancer treatment and research - including innovations in diagnostic, surgical, chemotherapy and radiation approaches - will be discussed Friday, April 8, 2011, at a breast cancer symposium at the Kimmel Cancer Center at Jefferson in Philadelphia.
On September 24th at 7:00pm EDT, Dr. Holly Andersen, Director of Education and Outreach at the Ronald O. Perelman Heart Institute at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, will host a live webcast exploring the advances and innovations in the treatment of cardiovascular disease. The air live on ORLive.com from the Hospital's new Ronald O. Perelman Heart Institute.
Itamar-Medical, the world's leader of non-invasive devices for diagnosis of cardiovascular health, announced achievement of the next milestone of the international pharmaceutical company, Roche, to further develop the EndoPAT technology for pre-clinical trials.
Watson Pharmaceuticals, Inc. has announced that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for albuterol sulfate inhalation solution in the 0.021% (base) and 0.042% (base) strengths.
An international research team, led by the University of Bristol, has provided the first clues to understand how the mcr-1 gene protects bacteria from colistin - a 'last resort' antibiotic used to treat life-threatening bacterial infections that do not respond to other treatment options.
› Verified 4 days ago
Dr. John S Tkach, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2315 N 5th St, Elko, NV 89801 Phone: 775-753-6400 Fax: 775-753-3551 | |
Dr. Brad S. Burlew, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1775 Browning Way Ste 104, Elko, NV 89801 Phone: 775-738-5100 Fax: 775-738-5115 | |
Dr. Michelle Hryniuk, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1780 Browning Way, Elko, NV 89801 Phone: 775-778-0386 | |
Dr. Chad E Quintero, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 2001 Errecart Blvd, Elko, NV 89801 Phone: 561-762-0049 Fax: 702-453-5741 | |
Felix Quinto Deguzman, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1993 Errecart Blvd, Elko, NV 89801 Phone: 775-753-1049 Fax: 775-777-8494 | |
Dr. Paton G Whimple, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1995 Errecart Blvd Ste 107, Elko, NV 89801 Phone: 775-777-1895 Fax: 775-777-1897 |